[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
Abstract
Acquired hemophilia A (AHA) is a rare and potentially severe bleeding disorder caused by circulating autoantibodies directed against factor (F) VIII. Apart from idiopathic cases, AHA is associated with autoimmune diseases, cancers, use of medications, pregnancy and the post-partum period. We report the case of a 78-year-old a male patient presenting with symptoms of a hematoma after a fall three days previously. He is medically followed for multiple myeloma and bullous pemphigoid. Laboratory investigations revealed isolated and recent increased of activated partial thromboplastin time (80,6/32,1s) and a markedly low FVIII activity (< 1%). The high-titer of FVIII inhibitor (19 Bethesda units/mL) confirmed the diagnosis of AHA diagnosis. The symptoms were noticeably alleviated following bortezomib, cyclophosphamide and dexamethasone therapy. This report describes a rare case of AHA associated with bullous pemphigoid and multiple myeloma. These pathologies induce an immunity modification that can predispose or be associated with the development of anti-FVIII inhibitors. This case illustrates two possible physiopathological hypotheses for the development of AHA, which will be discussed in this case report.
Related
- Case Report: bullous pemphigoid during secukinumab treatment for plaque psoriasis: therapeutic challenges and long-term follow-up
- Acquired hemophilia A: an illustrated review based on the French National Guidelines
- Case Report: Relapsed acquired hemophilia A following prednisone-rituximab therapy successfully treated with orelabrutinib
- Choroid plexus remodeling associated with inflammatory CSF exposure in preterm acquired hydrocephalus
- Community-acquired rhinovirus infection is associated with changes in the airway microbiome
BibTeX
@article{sourdeau2026acquired,
title = {{[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].}},
author = {Sourdeau É and Clauser S and Prud'Homme R and Valérie Bardet and Calmette L},
journal = {Annales de Biologie Clinique},
year = {2026},
month = oct,
doi = {10.1684/abc.2018.1405},
url = {https://hal.science/hal-05785529v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
AU - Sourdeau É
AU - Clauser S
AU - Prud'Homme R
AU - Valérie Bardet
AU - Calmette L
PY - 2026
DA - 2026/10/08
JO - Annales de Biologie Clinique
DO - 10.1684/abc.2018.1405
UR - https://hal.science/hal-05785529v1
AB - Acquired hemophilia A (AHA) is a rare and potentially severe bleeding disorder caused by circulating autoantibodies directed against factor (F) VIII. Apart from idiopathic cases, AHA is associated with autoimmune diseases, cancers, use of medications, pregnancy and the post-partum period. We report the case of a 78-year-old a male patient presenting with symptoms of a hematoma after a fall three days previously. He is medically followed for multiple myeloma and bullous pemphigoid. Laboratory investigations revealed isolated and recent increased of activated partial thromboplastin time (80,6/32,1s) and a markedly low FVIII activity (< 1%). The high-titer of FVIII inhibitor (19 Bethesda units/mL) confirmed the diagnosis of AHA diagnosis. The symptoms were noticeably alleviated following bortezomib, cyclophosphamide and dexamethasone therapy. This report describes a rare case of AHA associated with bullous pemphigoid and multiple myeloma. These pathologies induce an immunity modification that can predispose or be associated with the development of anti-FVIII inhibitors. This case illustrates two possible physiopathological hypotheses for the development of AHA, which will be discussed in this case report.
SN - 0003-3898
ER -